



Zymeworks Appoints Dr. Richard Lavery to its Scientific Advisory Board

October 31, 2008

VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held computational biotechnology company, today announced the appointment of Dr. Richard Lavery to its scientific advisory board.

Dr. Lavery is a world-renowned expert on the development and application of molecular mechanics, molecular dynamics, and conformational analysis on nucleic acid and protein systems. He is the author of over 170 peer-reviewed articles, 15 book chapters and the co-editor of 5 books. He is currently the Head of the Department of Molecular Biostructures at the Institut de Biologie et Chimie des Protéines (IBCP) in Lyon. Dr. Lavery is also the recent President of the International Society of Quantum Biology and Pharmacology and a member of the EPSRC Peer Review College (UK). Additionally, he serves on the editorial boards of prestigious journals such as The European Journal of Chemical Physics and Physical Chemistry (ChemPhysChem), the Journal of Computational Chemistry, Theoretical Chemistry Accounts, and Open Chemical Physics Journal. Dr. Lavery was a Fellow of Churchill College, Cambridge University, UK and Director of the Theoretical Biochemistry Laboratory at the Institute de Biologie Physico-Chimique in Paris. Dr. Lavery has a doctoral degree from the University of Paris and Ph.D. and B.Sc. degrees from the University of Manchester, UK.

“As we continue to advance the ZymeCAD™ platform, Richard’s expertise will be invaluable in guiding Zymeworks’ scientific and technical teams,” says Dr. Ali Tehrani, President and CEO of Zymeworks. “We are looking to work closely with Richard and other members of our scientific advisory board to position Zymeworks as a global leader in the field of computation biotechnology and protein engineering.”

About Zymeworks Inc.

Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop protein therapeutics and industrial enzymes. Zymeworks’ proprietary ZymeCAD™ molecular simulation platform creates a highly detailed modeling environment that generates novel physical and chemical insights into protein systems. Zymeworks’ protein engineers utilize these new understandings into structure-function relationships to accurately modify proteins to address customers’ needs and to advance Zymeworks’ protein therapeutics pipeline. More information on Zymeworks can be found at <http://www.zymeworks.com>.

Contact:

Zymeworks Inc.

Manager, Business Development

604-678-1388, info@zymeworks.com

Source: Zymeworks Inc.